Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 20 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC, a life sciences focused venture capital firm. Prior to ETP he was a vice president and portfolio manager at T. Rowe Price, where his responsibilities included managing $2 billion of mutual fund and institutional client portfolios. Some of Mr. Snider’s past directorships include Alpha Innotech, Molecular Transfer, and Atto Biosciences, and he currently serves on the boards of Astero Bio, BioInformatics, and the MdBio Foundation. He has made more than 30 growth capital investments while at BroadOak, and looks forward to making 30 more.

Bill holds the Chartered Financial Analyst accreditation, and graduated without honors, twice, from the Wharton School at the University of Pennsylvania: once to earn a B.S.E. in Finance, and later, an M.B.A. His golf game hasn’t improved in the last 20 years, and he suspects he might be better at tennis. Bill has been dedicated to youth rowing since his daughter entered high school; he discovered his passion for crew when he walked onto the team at Penn.

Dr. Shahram Hejazi is a medical device/life science executive with general management experience in both early-stage ventures and large global companies. As a Venture Partner with BioAdvance, he is responsible for investments in device, diagnostics and imaging field. Previously, Dr. Hejazi was the President of Kodak’s life science division (now called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing and service. Before Kodak, he was the CEO of Zargis Medical Corporation (an early-stage medical device company that spun off from Siemens), where he led the company’s efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval and product launch. Prior to Zargis, Dr. Hejazi was the Head of the Strategic Business Development group at Siemens, responsible for identifying early-stage growth/investment opportunities and new business development in the medical field.

Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc., he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45%, and exited the company through its sale to Pall Corporation, returning $160M to investors. During his 9-year tenure at Molecular Devices Corporation, Dr. Keegan grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company, where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Board of Directors of Arrayjet LTD, Bio-Techne (NASDAQ:TECH), Carterra, Interpace Diagnostics (NASDAQ:IDXG), Labcyte as Chairman and Nanomedical Diagnostics as Executive Chairman. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Souvignier conducts the scientific and business analysis of early-stage biomedical investment opportunities for RCT and also manages a portfolio of projects and investments for RCT. His areas of focus at RCT include oncology, pain, central nervous system disorders, diabetes and metabolic disease.

Rick comes to Halo Labs with over 15 years of experience in start-up, emerging growth, and market-leading life science tools companies. Prior to joining Halo Labs, Rick held senior positions at Unchained Labs and Phasefocus, where he launched and built sales organizations and was a key member of the team that grew ForteBio into the bestselling label-free protein characterization platform on the market. Rick has also held sales positions at Molecular Devices, LabKey Software, and Pacific Biomarkers. Rick holds a B.S. in Biology from the University of Washington and an M.S. in Biology from the University of Maine.